Search Results - "WELCH, ANDREW A."

Improving Intravenous and Subcutaneous Insulin Overlap During Treatment of Diabetic Ketoacidosis: A Quality Improvement Project by Welch, Andrew A., Toro-Tobon, David, Rachmasari, Kharisa N., Sandooja, Rashi B., Rahimi, Leili, Mohan, Sneha, Hewlett, Jennifer R., Clark, Jennifer, Maheshwari, Arvind, Zhang, Catherine, Brito, Juan P.

“…To reduce the frequency of insufficient overlap of intravenous (IV) and subcutaneous (SC) insulin during the treatment of diabetic ketoacidosis (DKA) as a…”
Get full text

1936-LB: The Challenge of Obtaining Diabetes Technology Supplies in Adults with Type 1 Diabetes by WELCH, ANDREW A., KNOERL, THOMAS, KOPRAS, ELIZABETH J., CORATHERS, SARAH, FALCIGLIA, MERCEDES

“…Background: Individuals with Type 1 Diabetes (T1D) face barriers to reliably obtain prescribed technology supplies (continuous glucose monitors [CGM]/insulin…”
Get full text

The Effect of Glucagon-Like Peptide 1 Receptor Blockade on Glucagon-Induced Stimulation of Insulin Secretion by Farahani, Rahele A, Egan, Aoife M, Welch, Andrew A, Laurenti, Marcello C, Cobelli, Claudio, Dalla Man, Chiara, Vella, Adrian

“…Data from transgenic rodent models suggest that glucagon acts as an insulin secretagogue by signaling through the glucagon-like peptide 1 receptor (GLP-1R)…”
Get full text

1547-P: The Differential Effect of Glucagon-Like Peptide-1 Receptor Blockade on Glucose Metabolism in People With and Without Type 2 Diabetes by WELCH, ANDREW A., FARAHANI, RAHELE A., ZEINI, MAYA, EGAN, AOIFE M., LAURENTI, MARCELLO C., COBELLI, CLAUDIO, DALLA MAN, CHIARA, VELLA, ADRIAN

“…Glucagon-Like Peptide-1 (GLP-1) is present within the islet but the effects of GLP-1 Receptor (GLP1R) blockade on islet function in humans remains unknown. To…”
Get full text

36-OR: The Effect of Glucagon-Like Peptide-1 Receptor Blockade on the ß-Cell Response to Glucagon Bolus in People With and Without Type 2 Diabetes by EGAN, AOIFE M., ZEINI, MAYA, WELCH, ANDREW A., FARAHANI, RAHELE A., LAURENTI, MARCELLO C., COBELLI, CLAUDIO, DALLA MAN, CHIARA, VELLA, ADRIAN

“…Glucagon acts as an insulin secretagogue in part via the glucagon-like peptide-1 receptor (GLP1R) expressed on β-cells. Type 2 diabetes (DM2) is characterized…”
Get full text

1646-P: The Effect of Glucagon-Like Peptide-1 Receptor Blockade and Acute Insulin Resistance on Islet Function and Glucose Metabolism in People without Diabetes by ZEINI, MAYA, FARAHANI, RAHELE A., WELCH, ANDREW A., LAURENTI, MARCELLO C., COBELLI, CLAUDIO, DALLA MAN, CHIARA, EGAN, AOIFE M., VELLA, ADRIAN

“…Intra-islet Glucagon-Like Peptide-1 (GLP-1) is increased by islet inflammation and diabetes. GLP-1 Receptor (GLP1R) blockade with exendin-9,39 impairs fasting…”
Get full text

Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humans by Welch, Andrew A, Farahani, Rahele A, Egan, Aoife M, Laurenti, Marcello C, Zeini, Maya, Vella, Max, Bailey, Kent R, Cobelli, Claudio, Dalla Man, Chiara, Matveyenko, Aleksey, Vella, Adrian

“…BACKGROUNDProglucagon can be processed to glucagon-like peptide1 (GLP-1) within the islet, but its contribution to islet function in humans remains unknown. We…”
Get full text

1325-P: Modulation of Overnight Free Fatty Acid and Glucose Concentrations and Their Effect on Postprandial Islet Function and Glucose Metabolism by WELCH, ANDREW A., SCHEMBRI WISMAYER, DANIEL, EGAN, AOIFE M., FARAHANI, RAHELE A., LAURENTI, MARCELLO C., COBELLI, CLAUDIO, DALLA MAN, CHIARA, VELLA, ADRIAN

“…Individuals with prediabetes can be classified by fasting and glucose tolerance status. Previously we observed that elevated fasting Free Fatty Acids (FFA) are…”
Get full text

358-OR: The Effect of Glucagon-Like Peptide-1 Receptor Blockade on Glucagon-Induced Stimulation of Insulin Secretion by FARAHANI, RAHELE A., EGAN, AOIFE M., WELCH, ANDREW A., LAURENTI, MARCELLO C., COBELLI, CLAUDIO, DALLA MAN, CHIARA, VELLA, ADRIAN

“…Data from transgenic rodent models suggest that glucagon acts as an insulin secretagogue by signalling through the Glucagon-Like Peptide-1 Receptor (GLP1R)…”
Get full text

Effects of acute changes in fasting glucose and free fatty acid concentrations on indices of β-cell function and glucose metabolism in subjects without diabetes by Schembri Wismayer, Daniel, Laurenti, Marcello C, Song, Yilin, Egan, Aoife M, Welch, Andrew A, Bailey, Kent R, Cobelli, Claudio, Dalla Man, Chiara, Jensen, Michael D, Vella, Adrian

“…Elevated fasting free fatty acids (FFAs) and fasting glucose are additively associated with impaired glucose tolerance (IGT) and decreased β-cell function…”
Get more information

1238-P: Utilization of Comprehensive Pharmacy Services in Diabetes Care Coordination for Hospitalized Patients by WELCH, ANDREW A., BOESKEN, TIMMI ANNE, WOOLF, BRITTANY, BERGER, KIMBERLY, CORBIN, ADELE, BACHMAN, NICHOLE E., SCHAUER, DANIEL, FALCIGLIA, MERCEDES

“…A major barrier to effective diabetes care is difficulty with affording and knowing how to use medications. At a 750-bed urban hospital, comprehensive pharmacy…”
Get full text